Differential protein expression between normal, early-stage, and late-stage myxomatous mitral valves from dogs

Proteomics - Clinical Applications

Volumn 3, Issue 12, 2009, Pages 1422-1429

  Lacerda, Carla M R ^a   Disatian, Sirilak ^a   Orton, E Christopher ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Myxomatous valve disease; Quantitative proteomics

Indexed keywords

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; HEART MYXOMA; IMMUNOBLOTTING; MALE; MITRAL VALVE DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; UPREGULATION;

CANIS FAMILIARIS;

EID: 77951048361     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900066     Document Type: Article

References (27)

1. Caira, F. C., Stock, S. R., Gleason, T. G., McGee, E. C. et al., Human degenerative valve disease is associated with upregulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol. 2006, 47, 1707-1712.
2. Freed, L. A., Levy, D., Levine, R. A., Larson, M. G. et al., Prevalence and clinical outcome of mitral-valve prolapse. N. Engl. J. Med. 1999, 341, 1-7.
3. Das, K. M., Tashjian, R. J., Chronic mitral valve disease in the dog. Vet. Med. Small Anim. Clin. 1965, 60, 1209-1216.
4. Detweiler, D. K., Patterson, D. F., The prevalence and types of cardiovascular disease in dogs. Ann. NY Acad. Sci. 1965, 127, 481-516.
5. Pellerin, D., Brecker, S., Veyrat, C., Degenerative mitral valve disease with emphasis on mitral valve prolapse. Heart 2002, 88, 20-28.
6. Schoen, F. J., Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc. Pathol. 2005, 14, 189-194.
7. Pedersen, H. D., Haggstrom, J., Mitral valve prolapse in the dog: a model of mitral valve prolapse in man. Cardiovasc. Res. 2000, 47, 234-243.
8. Devereux, R. B., Brown, W. T., Kramer-Fox, R., Sachs, I., Inheritance ofmitral valve prolapse: effect of age and sex on gene expression. Ann. Intern. Med. 1982, 97, 826-832.
9. Pedersen, H. D., Kristensen, B. O., Lorentzen, K. A., Koch, J. et al., Mitral valve prolapse in 3-year-old healthy Cavalier King Charles Spaniels. An echocardiographic study. Can. J. Vet. Res. 1995, 59, 294-298.
10. Kittleson, M. D., Kienle, R. D., Small Animal Cardiovascular Medicine, Mosby, St. Louis, MO 1998, pp. viii, 603.
11. Schurch, W., Seemayer, T. A., Gabbiani, G., The myofibroblast: a quarter century after its discovery. Am. J. Surg. Pathol. 1998, 22, 141-147.
12. Mulholland, D. L., Gotlieb, A. I., Cell biology of valvular interstitial cells. Can. J. Cardiol. 1996, 12, 231-236.
13. Rabkin-Aikawa, E., Farber, M., Aikawa, M., Schoen, F. J., Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 2004, 13, 841-847.
14. Taylor, P. M., Batten, P., Brand, N. J., Thomas, P. S. et al., The cardiac valve interstitial cell. Int. J. Biochem. Cell Biol. 2003, 35, 113-118.
15. Aikawa, M., Sugiyama, S., Hill, C. C., Voglic, S. J. et al., Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002, 106, 1390-1396.
16. Rabkin, E., Aikawa, M., Stone, J. R., Fukumoto, Y. et al., Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104, 2525-2532.
17. Rabkin, E., Hoerstrup, S. P., Aikawa, M., Mayer, J. E., Jr. et al., Evolution of cell phenotype and extracellular matrix in tissue-engineered heart valves during in-vitro maturation and in-vivo remodeling. J. Heart Valve Dis. 2002, 11, 308-314; discussion 314.
18. Schmitt-Graff, A., Desmouliere, A., Gabbiani, G., Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch. 1994, 425, 3-24.
19. Taylor, P. M., Allen, S. P., Yacoub, M. H., Phenotypic and functional characterization of interstitial cells from human heart valves, pericardium and skin. J. Heart Valve Dis. 2000, 9, 150-158.
20. Disatian, S., Ehrhart, E. J., 3rd, Zimmerman, S., Orton, E. C., Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J. Heart Valve Dis. 2008, 17, 402-411; discussion 412.
21. Pomerance, A., Whitney, J. C., Heart valve changes common to man and dog: a comparative study. Cardiovasc. Res. 1970, 4, 61-66.
22. Saeed, A. I., Sharov, V., White, J., Li, J. et al., TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34, 374-378.
23. Kogure, K., Pathology of chronic mitral valvular disease in the dog. Nippon Juigaku Zasshi 1980, 42, 323-335.
24. Oyama, M. A., Chittur, S. V., Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am. J. Vet. Res. 2006, 67, 1307-1318.
25. Disatian, S., Orton, E. C., Autocrine serotonin and transforming growth factor b 1 signaling mediates spontaneous myxomatous mitral valve disease. J. Heart Valve Dis. 2009, 18, 44-51.
26. Winge, I., McKinney, J. A., Ying, M., D'Santos, C. S. et al., Activation and stabilization of human tryptophan hydroxylase 2 by phosphorylation and 14-3-3 binding. Biochem. J. 2008, 410, 195-204.
27. Skonier, J., Bennett, K., Rothwell, V., Kosowski, S. et al., Beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol. 1994, 13, 571-584.